Key facts
- Axena Health’s last known valuation is $70.0M (Apr 2026).
- It has raised $45.9M across 2 recorded rounds; the latest was Early Stage VC ($15.0M) in Dec 2025.
- Notable investors include Catalio Capital Management, AXA Investment Managers, AARP, AgeTech Collaborative from AARP, Avestria Ventures — 7 tracked in total.
- Axena Health has filed 2 Form Ds with the SEC since 2023, most recently Apr 2026 ($15.0M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Axena Health
Funding rounds
2 roundsAbout Axena Health
Developer of a connected medical device designed to improve outcomes for women with pelvic floor disorders. The company's platform offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions, its patented technology enables non-invasive, drug-free treatment via precise visualization of movement in real-time while monitoring usage and progress, enabling women to strengthen their pelvic floor and decrease the symptoms of stress, mixed and urgency incontinence, including overactive bladder.
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2023
- Employees
- 47
- Website
- axenahealth.com/
- Ownership
- Privately Held (backing)
Axena Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axena Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axena Health in its N-PORT filings yet. We sweep new filings monthly.